Is a deep response the key to the successful treatment of multiple myeloma?

Several authors have highlighted the importance of a good response to chemotherapy in multiple myeloma (MM), especially in first line. We assessed whether a deep response is prognostic for overall survival (OS) independent of treatment, treatment line and patient/disease characteristics based on a Nordic RWE dataset of 3000 patients. Multivariate cox-regressions show that in the

Lees meer

Can overall survival be improved in elderly multiple myeloma patients?

The ongoing introduction of novel therapies for MM provides clinicians and patients various treatment options in numerous lines of treatment. Understanding the current treatment practices and the corresponding outcomes in different age groups is of vital importance to understand whether these new treatments should be used in patients from all age groups and where options

Lees meer

Trial efficacy vs real world effectiveness in multiple myeloma

Real world evidence (RWE) is increasingly important in guiding reimbursement, but also treatment decisions, as HTAs, health insurers and clinicians are increasingly interested in the true real world (relative) effectiveness rather than the trials’ ideal (relative) efficacy. This requires combining and or comparing RWE effectiveness data with efficacy trial data. The primary aim of the

Lees meer

Welcome Lewis to Ingress-health

Sze Chim (Lewis) obtained a  PhD (Dr. rer. nat.) in Biology from Eberhard Karls Universität Tübingen, Germany. His dissertation topic was to characterize the auditory phenotypes of mice with specific genetic mutations. He has also a Master (MSc) degree in Psychological Research Methods from Lancaster, UK. His PhD study in Tübingen involved performing pre-clinical studies to look for

Lees meer

INGRESS Health Germany has relocated

INGRESS Health has recently moved from the University Campus of Wismar to Wismar’s beautiful waterfront. You can now find us at the Technology and Industrial Centre (TGZ) at Alter Holzhafen 19, 23966 Wismar. Please feel free to visit us at our new offices to discuss projects while enjoying the view.

Lees meer

Non adherence and persistence problematic in RA patients treated with MTX

We assessed a German claims database of in total 62,204 RA-patients of which 7,146 patients with a MTX therapy were observed. Non persistence was defined as a medication gap of more than 12 or 24 weeks and non adherence was defined as a medication possession ratio (MPR) of <80%. Our analyses showed that about 20%

Lees meer

Mahmoud Hashim has joined the Ingress-health team

Mahmoud is a physician with two MSc degrees in European sustainable health systems and public health. He has two years of professional experience as a researcher in Health Economics and Outcomes Research in Italy and Hungary where he mostly worked with oncologic products’ value dossiers. Besides, he has three years of experience in Pharmacovigilance and literature

Lees meer

Adherence Barriers Questionnaire (ABQ) published in BMC Health Services Research

INGRESS/IPAM developed the “Adherence Barriers Questionnaire (ABQ)” which is the first questionnaire that realiably measures causes of patients’ non-adherence. We validated the questionnaire both based on internal criteria and external comparison with clinical outcomes. Results of this validation have been published in BMC Health Services Research. If you are interested in applying the ABQ, please

Lees meer